You just read:

Results Announced for Phase III Head-to-head Study of Halaven® (eribulin) Versus Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer

News provided by

Eisai Europe Limited

07 Dec, 2012, 13:30 GMT